Arkolith/Insider Trading/ENSC/Form 4

Kirkpatrick Lynn

Chief Executive Officer, DirectorEnsysce Biosciences, Inc. (ENSC) · full profile →Form 4 · filed Jul 2, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
1 non-derivative · 7 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 30, 2021Grant(A)285K——285K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 30, 2021Grant(A)7K——7K
Jun 30, 2021Grant(A)461K——461K
Jun 30, 2021Grant(A)818K——818K
Jun 30, 2021Grant(A)659K——659K
Jun 30, 2021Grant(A)263K——263K
Jun 30, 2021Grant(A)10K——10K
Jun 30, 2021Grant(A)100K——100K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001192482-21-000618) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Ensysce Biosciences, Inc.

Build

Ask your agent about ENSC insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001192482-21-000618"
Ask your agent
Use Arkolith to summarize insider buying and selling at Ensysce Biosciences, Inc.
over the last 90 days and cite the filings.